Anti-Obesity Therapeutics Market Report

Europe Anti-Obesity Therapeutics Market Size, Status and Forecast 2014-2026

  • POSTDATE：Feb 17, 2020
  • PAGES：217
  • REPORT CODE：GMM475204
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Anti-Obesity Therapeutics market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.3% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Anti-Obesity Therapeutics Market Segmentations:

    By Player:

    • Takeda Pharmaceutical

    • FlaxoSithKline plc

    • Shionogi USA

    • Novo Nordisk

    • Vivus.

    • Norgine Pharmaceuticals Ltd

    • Eisai Company

    • Rhythm Pharmaceuticals.

    • Alizyme

    • BoehringerIngelheim GmbH

    • Zafgen

    • Pfizer

    • Bristol-Myers Squibb

    By Type:

    • Centrally Acting Anti-obesity Drugs

    • Peripherally Acting Anti-obesity Drugs

    By End-User:

    • Hospital Use

    • Clinic Use

    • Household

    • Other

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Anti-Obesity Therapeutics Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs from 2014 to 2026

    • 1.3.2 Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Hospital Use from 2014 to 2026

    • 1.4.2 Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Clinic Use from 2014 to 2026

    • 1.4.3 Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Household from 2014 to 2026

    • 1.4.4 Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Other from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Anti-Obesity Therapeutics Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Anti-Obesity Therapeutics by Major Types

      • 3.4.1 Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs

      • 3.4.2 Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs

    4 Segmentation of Anti-Obesity Therapeutics Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Anti-Obesity Therapeutics by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Anti-Obesity Therapeutics for Hospital Use

      • 4.4.2 Market Size and Growth Rate of Anti-Obesity Therapeutics for Clinic Use

      • 4.4.3 Market Size and Growth Rate of Anti-Obesity Therapeutics for Household

      • 4.4.4 Market Size and Growth Rate of Anti-Obesity Therapeutics for Other

    5 Market Analysis by Major Regions

    • 5.1 Europe Anti-Obesity Therapeutics Production Analysis by Top Regions

    • 5.2 Europe Anti-Obesity Therapeutics Consumption Analysis by Top Regions

    • 5.3 Europe Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.3 France Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    6 Product Circulation of Anti-Obesity Therapeutics Market among Top Countries

    • 6.1 Top 5 Export Countries in Anti-Obesity Therapeutics Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Anti-Obesity Therapeutics Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Anti-Obesity Therapeutics Landscape Analysis

    • 7.1 Germany Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 7.2 Germany Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    8. UK Anti-Obesity Therapeutics Landscape Analysis

    • 8.1 UK Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 8.2 UK Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    9. France Anti-Obesity Therapeutics Landscape Analysis

    • 9.1 France Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 9.2 France Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    10. Italy Anti-Obesity Therapeutics Landscape Analysis

    • 10.1 Italy Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 10.2 Italy Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    11. Spain Anti-Obesity Therapeutics Landscape Analysis

    • 11.1 Spain Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 11.2 Spain Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    12. Poland Anti-Obesity Therapeutics Landscape Analysis

    • 12.1 Poland Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 12.2 Poland Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    13. Russia Anti-Obesity Therapeutics Landscape Analysis

    • 13.1 Russia Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 13.2 Russia Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    14. Switzerland Anti-Obesity Therapeutics Landscape Analysis

    • 14.1 Switzerland Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 14.2 Switzerland Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    15. Turkey Anti-Obesity Therapeutics Landscape Analysis

    • 15.1 Turkey Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 15.2 Turkey Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Landscape Analysis by Top Countries

      • 16.3.1 Denmark Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 16.3.2 Finland Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 16.3.3 Norway Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 16.3.4 Sweden Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 16.3.6 Iceland Anti-Obesity Therapeutics Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Landscape Analysis by Top Countries

      • 17.3.1 Belgium Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 17.3.2 Netherlands Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 17.3.3 Luxembourg Anti-Obesity Therapeutics Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Landscape Analysis by Top Countries

      • 18.3.1 Estonia Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 18.3.2 Latvia Anti-Obesity Therapeutics Market Volume and Growth Rate

      • 18.3.3 Lithuania Anti-Obesity Therapeutics Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Takeda Pharmaceutical

      • 19.1.1 Takeda Pharmaceutical Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 FlaxoSithKline plc

      • 19.2.1 FlaxoSithKline plc Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Shionogi USA

      • 19.3.1 Shionogi USA Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Novo Nordisk

      • 19.4.1 Novo Nordisk Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Vivus.

      • 19.5.1 Vivus. Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Norgine Pharmaceuticals Ltd

      • 19.6.1 Norgine Pharmaceuticals Ltd Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Eisai Company

      • 19.7.1 Eisai Company Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Rhythm Pharmaceuticals.

      • 19.8.1 Rhythm Pharmaceuticals. Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Alizyme

      • 19.9.1 Alizyme Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 BoehringerIngelheim GmbH

      • 19.10.1 BoehringerIngelheim GmbH Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Zafgen

      • 19.11.1 Zafgen Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Pfizer

      • 19.12.1 Pfizer Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Bristol-Myers Squibb

      • 19.13.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    The List of Tables and Figures (Totals 81 Figures and 116 Tables)

    • Figure Product Picture

    • Figure Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs from 2014 to 2026

    • Figure Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs from 2014 to 2026

    • Figure Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Hospital Use from 2014 to 2026

    • Figure Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Clinic Use from 2014 to 2026

    • Figure Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Household from 2014 to 2026

    • Figure Europe Anti-Obesity Therapeutics Market Size and Growth Rate of Other from 2014 to 2026

    • Figure Germany Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure UK Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure France Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Anti-Obesity Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Anti-Obesity Therapeutics Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Anti-Obesity Therapeutics

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Anti-Obesity Therapeutics by Different Types from 2014 to 2026

    • Table Consumption Share of Anti-Obesity Therapeutics by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs

    • Figure Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Anti-Obesity Therapeutics by Different End-Users from 2014 to 2026

    • Table Consumption Share of Anti-Obesity Therapeutics by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospital Use

    • Figure Market Size and Growth Rate of Clinic Use

    • Figure Market Size and Growth Rate of Household

    • Figure Market Size and Growth Rate of Other

    • Table Europe Anti-Obesity Therapeutics Production by Major Regions

    • Table Europe Anti-Obesity Therapeutics Production Share by Major Regions

    • Figure Europe Anti-Obesity Therapeutics Production Share by Major Countries and Regions in 2014

    • Table Europe Anti-Obesity Therapeutics Consumption by Major Regions

    • Table Europe Anti-Obesity Therapeutics Consumption Share by Major Regions

    • Table Germany Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table UK Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table France Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Italy Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Spain Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Poland Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Russia Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Switzerland Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Turkey Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Anti-Obesity Therapeutics Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Germany Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Germany Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Germany Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table UK Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table UK Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table UK Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table UK Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table France Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table France Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table France Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table France Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Italy Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Italy Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Italy Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Italy Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Spain Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Spain Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Spain Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Spain Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Poland Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Poland Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Poland Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Poland Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Russia Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Russia Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Russia Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Russia Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Switzerland Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Switzerland Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Switzerland Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Turkey Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Turkey Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Turkey Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-Obesity Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-Obesity Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-Obesity Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Anti-Obesity Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Takeda Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Takeda Pharmaceutical

    • Figure Revenue and Market Share Analysis of Takeda Pharmaceutical

    • Table Product and Service Introduction of Takeda Pharmaceutical

    • Table Company Profile and Development Status of FlaxoSithKline plc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of FlaxoSithKline plc

    • Figure Sales and Growth Rate Analysis of FlaxoSithKline plc

    • Figure Revenue and Market Share Analysis of FlaxoSithKline plc

    • Table Product and Service Introduction of FlaxoSithKline plc

    • Table Company Profile and Development Status of Shionogi USA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shionogi USA

    • Figure Sales and Growth Rate Analysis of Shionogi USA

    • Figure Revenue and Market Share Analysis of Shionogi USA

    • Table Product and Service Introduction of Shionogi USA

    • Table Company Profile and Development Status of Novo Nordisk

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk

    • Figure Sales and Growth Rate Analysis of Novo Nordisk

    • Figure Revenue and Market Share Analysis of Novo Nordisk

    • Table Product and Service Introduction of Novo Nordisk

    • Table Company Profile and Development Status of Vivus.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Vivus.

    • Figure Sales and Growth Rate Analysis of Vivus.

    • Figure Revenue and Market Share Analysis of Vivus.

    • Table Product and Service Introduction of Vivus.

    • Table Company Profile and Development Status of Norgine Pharmaceuticals Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Norgine Pharmaceuticals Ltd

    • Figure Sales and Growth Rate Analysis of Norgine Pharmaceuticals Ltd

    • Figure Revenue and Market Share Analysis of Norgine Pharmaceuticals Ltd

    • Table Product and Service Introduction of Norgine Pharmaceuticals Ltd

    • Table Company Profile and Development Status of Eisai Company

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eisai Company

    • Figure Sales and Growth Rate Analysis of Eisai Company

    • Figure Revenue and Market Share Analysis of Eisai Company

    • Table Product and Service Introduction of Eisai Company

    • Table Company Profile and Development Status of Rhythm Pharmaceuticals.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Rhythm Pharmaceuticals.

    • Figure Sales and Growth Rate Analysis of Rhythm Pharmaceuticals.

    • Figure Revenue and Market Share Analysis of Rhythm Pharmaceuticals.

    • Table Product and Service Introduction of Rhythm Pharmaceuticals.

    • Table Company Profile and Development Status of Alizyme

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alizyme

    • Figure Sales and Growth Rate Analysis of Alizyme

    • Figure Revenue and Market Share Analysis of Alizyme

    • Table Product and Service Introduction of Alizyme

    • Table Company Profile and Development Status of BoehringerIngelheim GmbH

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of BoehringerIngelheim GmbH

    • Figure Sales and Growth Rate Analysis of BoehringerIngelheim GmbH

    • Figure Revenue and Market Share Analysis of BoehringerIngelheim GmbH

    • Table Product and Service Introduction of BoehringerIngelheim GmbH

    • Table Company Profile and Development Status of Zafgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Zafgen

    • Figure Sales and Growth Rate Analysis of Zafgen

    • Figure Revenue and Market Share Analysis of Zafgen

    • Table Product and Service Introduction of Zafgen

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US